Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.
Matthew J. Frigault, MD
Advertisement
Articles by Matthew J. Frigault, MD
Matthew J. Frigault, MD, reviews the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma and real-world data supporting it's use.
Advertisement
Latest Updated Articles
Recent Developments in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaPublished: November 6th 2020 | Updated:
Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, LymphomasPublished: January 11th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
2
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
3
Guess the Therapy Answer October 16, 2025
4
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
5
